Chemical Compound Review:
CHEMBL907 2-butyl-5-chloro-3-[[4-[2- (2H-tetrazol-5...
Synonyms:
SureCN179, EXP-3174, AG-D-52606, SureCN2187501, ACMC-20mr6h, ...
- Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Goldberg, M.R., Lo, M.W., Deutsch, P.J., Wilson, S.E., McWilliams, E.J., McCrea, J.B. Clin. Pharmacol. Ther. (1996)
- Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Sica, D.A., Halstenson, C.E., Gehr, T.W., Keane, W.F. Clinical pharmacokinetics. (2000)
- Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats. Widdop, R.E., Gardiner, S.M., Bennett, T. Brain Res. (1994)
- Beta 2-adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human atria. Rump, L.C., Schwertfeger, E., Schaible, U., Fraedrich, G., Schollmeyer, P. Circ. Res. (1994)
- Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Allabi, A.C., Gala, J.L., Horsmans, Y., Babaoglu, M.O., Bozkurt, A., Heusterspreute, M., Yasar, U. Clin. Pharmacol. Ther. (2004)
- Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Yasar, U., Forslund-Bergengren, C., Tybring, G., Dorado, P., Llerena, A., Sjöqvist, F., Eliasson, E., Dahl, M.L. Clin. Pharmacol. Ther. (2002)
- Effect of EXP 3174 on blood pressure of normoreninemic renal hypertensive rats. Basso, N., Kurnjek, M.L., Ruiz, P., Cannata, M.A. Hypertension (1995)
- Effect of acute and chronic treatment with the angiotensin II subtype 1 receptor antagonist EXP 3174 on baroreflex function in conscious spontaneously hypertensive rats. Bartholomeusz, B., Widdop, R.E. J. Hypertens. (1995)
- HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II-induced trophic effects, fibronectin release and fibronectin-EIIIA+ expression in rat aortic vascular smooth muscle cells in vitro. Dunn, F.W., Roux, M.H., Farhadian, F., Sabri, K., Ossart, C., Samuel, J.L., Rappaport, L., Hamon, G. J. Pharmacol. Exp. Ther. (1997)
- Blocking hypothalamic AT1 receptors lowers blood pressure in salt-sensitive rats. Yang, R.H., Jin, H., Chen, S.J., Wyss, J.M., Oparil, S. Hypertension (1992)
- Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition. Zhang, X., Dunham, E.W., Zimmerman, B.G. J. Hypertens. (1995)
- Intrinsic properties of the nonpeptide angiotensin II antagonist losartan in glomeruli and mesangial cells at high concentrations. Chansel, D., Badre, L., Czekalski, S., Vandermeersch, S., Cambar, J., Ardaillou, R. J. Pharmacol. Exp. Ther. (1993)
- Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Soldner, A., Benet, L.Z., Mutschler, E., Christians, U. Br. J. Pharmacol. (2000)
- Beta-adrenergic, angiotensin II, and bradykinin receptors enhance neurotransmission in human kidney. Rump, L.C., Bohmann, C., Schaible, U., Schultze-Seemann, W., Schollmeyer, P.J. Hypertension (1995)
- Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists. González, L., Akesolo, U., Jiménez, R.M., Alonso, R.M. Electrophoresis (2002)
- In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation. Virone-Oddos, A., Desangle, V., Provost, D., Cazes, M., Caussade, F., Cloarec, A. Br. J. Pharmacol. (1997)
- Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Kaukonen, K.M., Olkkola, K.T., Neuvonen, P.J. Eur. J. Clin. Pharmacol. (1998)
- Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. Suzuki, J., Ohta, H., Hanada, K., Kawai, N., Ikeda, T., Nakao, M., Ikemoto, F., Nishikibe, M. Hypertens. Res. (2001)
- Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Sandwall, P., Lo, M.W., Jonzon, B., Dalén, P., Furtek, C., Ritter, M., Alván, G., McCrea, J., Sjöqvist, F. Eur. J. Clin. Pharmacol. (1999)
- Clinical pharmacokinetics of losartan. Sica, D.A., Gehr, T.W., Ghosh, S. Clinical pharmacokinetics. (2005)
- Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (imidazolylbiphenylyl)sulfonylurea (HR 720). Deprez, P., Guillaume, J., Becker, R., Corbier, A., Didierlaurent, S., Fortin, M., Frechet, D., Hamon, G., Heckmann, B., Heitsch, H. J. Med. Chem. (1995)
- The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. Marier, J.F., Guilbaud, R., Kambhampati, S.R., Mathew, P., Moberly, J., Lee, J., Salazar, D.E. Journal of clinical pharmacology. (2006)